A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Biovie Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 17,200 shares of BIVI stock, worth $47,644. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,200
Previous 51,700 66.73%
Holding current value
$47,644
Previous $27,000 77.78%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$1.22 - $5.24 $9,816 - $42,161
-8,046 Reduced 99.65%
28 $0
Q3 2023

Nov 14, 2023

BUY
$2.75 - $5.17 $22,203 - $41,742
8,074 New
8,074 $27,000
Q1 2023

May 15, 2023

SELL
$4.89 - $10.53 $66,528 - $143,260
-13,605 Reduced 89.52%
1,592 $12,000
Q4 2022

Feb 14, 2023

BUY
$3.86 - $42.0 $58,660 - $638,274
15,197 New
15,197 $118,000

Others Institutions Holding BIVI

About BIOVIE INC.


  • Ticker BIVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,165,300
  • Market Cap $83.6M
  • Description
  • BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...
More about BIVI
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.